Read Original Story

Weighing the options: With obesity surgery on rise, patients need to explore risks, rewards

Rating

4 Star

Weighing the options: With obesity surgery on rise, patients need to explore risks, rewards

Our Review Summary

This article does a fairly complete job of providing information on outcomes from different surgical approaches for treating morbid obesity in terms of magnitude of potential weight loss, cost, length of hospital stay, associated mortality rate, and other types of complications. But in terms of balance, it does not do a sufficient job of presenting the effects of calorie reduction on weight loss. To its credit, however, the piece mentions that no surgery will provide lasting weight loss unless there is sustained change to eating and exercise habits.

Criteria

Does the story adequately discuss the costs of the intervention?

Satisfactory

Table does a good job with this.

Does the story adequately quantify the benefits of the treatment/test/product/procedure?

Satisfactory

Table and

text disagree about weight loss for biliopancreatic diversion. Is it loss of 80% of excess weight for at least 10 years

(text) or loss of 60-80% of excess weight in a year (table)?

Does the story seem to grasp the quality of the evidence?

Not Satisfactory

Did not mention the source of the data used in the article.

Does the story commit disease-mongering?

Not Satisfactory

Because the article started by discussing weight loss in general, it should

have included information for people who are not candidates for surgery. Otherwise the story seems to frame obesity surgery

as a reasonble option for all trying to lose weight.

Does the story use independent sources and identify conflicts of interest?

Satisfactory

Interviewed some

clinicians involved in treating weight loss

Does the story compare the new approach with existing alternatives?

Satisfactory

Provided a reasonable overview of the treatment options; could have devoted more

attention to caloric reduction and activity increase.

Does the story establish the availability of the treatment/test/product/procedure?

Not Satisfactory

Did not indicate that banding and biliopancreatic diversion procedures are

not available everywhere. Implied but not explicit was the notion that vagus nerve stimulators and rimonabant were not

currently FDA approved at the time of publication.

Does the story establish the true novelty of the approach?

Satisfactory

Available approaches are

delineated from approaches that are being tested.

Total Score: 6 of 9 Satisfactory

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.